# Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

> **NCT05678322** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 26 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent
- **DEVICE:** PET MRI Imaging

## Key facts

- **NCT ID:** NCT05678322
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-31
- **Primary completion:** 2025-05-08
- **Final completion:** 2026-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05678322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05678322, "Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05678322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*